WASHINGTON -- Semaglutide (Wegovy) improved liver inflammation and fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH) through both weight loss-related and direct ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression of Alzheimer’s disease in closely watched trials, drugmaker Novo Nordisk ...

Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as two-year clinical trials end in disappointment for patients, medical ...

On November 24, Novo Nordisk announced that the GLP-1 mimetic semaglutide had failed to slow progression of Alzheimer’s disease in two Phase 3 trials. Even though the cat was out of the bag, ...

A massive real-world study comparing tirzepatide and semaglutide reveals both drugs deliver strong, early cardiovascular protection—reducing heart attack, stroke, and death in adults with type 2 ...

Common semaglutide side effects include nausea, vomiting, diarrhea, and constipation. These should get better with time. Avoid fatty and greasy foods, and eat smaller meals to minimize ...

The benefits of semaglutide, the active ingredient in popular drugs Ozempic and Wegovy, aren’t just limited to treating obesity. New research shows that semaglutide can protect people’s hearts ...

Recent clinical research indicates that semaglutide may effectively reverse weight gain and blood sugar issues caused by certain antipsychotic medications. A randomized trial demonstrated that ...

Semaglutide or tirzepatide should be first-line drugs for obesity and most of its related complications, new guidance from the European Association for the Study of Obesity recommended. The authors of ...

Please provide your email address to receive an email when new articles are posted on . Semaglutide positively affected renal fat mass, glomerular hemodynamics, inflammation and cortical fibrosis.